600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

• Mustafa Ozguroglu,
• Saadettin Kilickap,
• Igor Bondarenko,
• Ahmet Sezer,
• Mahmut Gümüş,
• Miranda Gogishvili,
• Xuanyao He,
• Giuseppe Gullo,
• Petra Rietschel,
• Ruben GW Quek

Affiliations

Mustafa Ozguroglu

11Cerrahpaşa School of Medicine, Istanbul, Turkey

Saadettin Kilickap

Cancer Institute, Department of Medical Oncology, Hacettepe University, Ankara, Turkey

Igor Bondarenko

12Oncology and Medical Radiology Department, Dnipro State Medical University, Dnipro, Ukraine

Ahmet Sezer

2Başkent University, Adana, Turkey

Mahmut Gümüş

3Istanbul Medeniyet University, Istanbul, Turkey

Miranda Gogishvili

6University Clinic Ltd, Tbilisi, Tbilisi, Georgia

Xuanyao He

7Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Giuseppe Gullo

7Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Petra Rietschel

7Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

Ruben GW Quek

7Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA